India

Pune hospital brings in advanced CAR-T therapy at a fraction of international costs | India News



PUNE: Sahyadri Hospitals, one of Maharashtra’s largest hospital chains has collaborated with ImmunoACT to introduce the CAR-T cell therapies in Pune. This CAR-T cell therapy is designed to treat relapsed or refractory B-cell lymphoma and B-acute lymphoblastic leukaemia patients aged 15 and above.
“The introduction of CAR-T cell therapy marks a significant leap in our commitment to providing cutting-edge care for cancer patients.This innovative approach reflects our continuous endeavour to push the boundaries of cancer treatment, offering patients the most advanced therapeutic options available,” states Abrarali Dalal, Director & CEO of Sahyadri Hospitals.
“The integration of CAR-T cell therapy sets a new benchmark in treating complex blood cancers, aligning with our mission to offer the highest standard of precision medicine.”
Commonly known as “living drugs,” these personalized therapies are manufactured by genetically modifying a patient’s own T-cells using a viral vector, specifically targeting certain types of cancer cells. NexCAR19, the first CAR-T therapy fully developed and manufactured in India, is now among approximately ten such therapies available commercially worldwide. While similar therapies can cost several hundred thousand dollars in the United States, it is planned to be offered at almost one-tenth of this cost.
Outcomes in B-cell cancers, where one or more lines of treatment have failed, are generally dismal. The hospital intends to deploy NexCAR19 to enhance the standard of care, which currently includes chemotherapy, monoclonal antibodies, and bone marrow transplant.
Dr. Shashikant Apte, MD, FRCPA, Head of the Department of Haematology & Bone Marrow Transplant Unit stated, “At our hospital approximately 45-50 bone marrow transplants are conducted annually. With the availability of NexCAR19, we now have a significant opportunity to improve outcomes and the quality of life for patients with B-cell malignancies. We hope that similar cell therapies will soon be accessible for other forms of haematological cancers, addressing a critically unmet need.”


#Pune #hospital #brings #advanced #CART #therapy #fraction #international #costs #India #News

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button